Reddit Posts
I might have what could be both the worst/best investment you can get for the next few months.
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Financial Services Stocks Moving Wednesday: UIHC, CIFR, LX, CACC, INTR, BFH, CB, ORGNW
Financial Services Stocks Moving Wednesday: UIHC, CIFR, LX, CACC, INTR, BFH, CB, ORGNW
Are Restaurants about to take a big hit to the chin in 2023?
Are Restaurants about to take a big hit to the chin in 2023?
Are Restaurants about to take a big hit to the chin in 2023?
Any idea what effect this might have on the stock market?
Bloomberg: Metals Haven’t Crashed This Hard Since the Great Recession
My Complete List of Stocks and Their Rankings By Sector/Industry
Daily Telegraph: Tesla faces challenges. The 1,000-kilometer mileage electric vehicle was broken by Mercedes-Benz, an established car manufacturer.
$LX an extremely undervalued stock that's meant to explode in January
Anyone scarred from $IPOF, check out OPFI ! it's a much better play 🚀🚀🚀🚀🚀🚀🚀🚀🚀
$HIMX - a potential Short squeeze play. GME X'mas special!
HIMAX DD (full credit to YieldFanatic) 🌈 🐻 please stop removing.
HIMAX and it’s fully autistic business (Full DD credit to YieldFanatic/YieldFanatic.com)
$HIMX - a huge potential value play. Extensive DD inside as well as my positions
$HIMX - a huge potential value play. Extensive DD inside. Position posted
$HIMX - a huge potential play - Extensive DD inside
$HIMX - a potential Short squeeze play. GME X'mas special!
HIMAX DD and it’s unusually autistic business. (Full credit to YieldFanatic)
Nio Stock Updates (What you need to know)
$NIO Investment Update (SEC Filings and Recent News)
$MITI Mitesco Sets Opening Dates for New Minneapolis Clinics, Additional Sites in Minneapolis and Denver Markets Expected to Follow
HIMX is a chip shortage play with solid outlook
$LX here's the deal, billion dollar company, easy 2x soon. They always short it before ER (August) because it goes up, because revenue is great. Squeeze em. Hold for a month can't lose regardless
I would buy $LX if I was you. Very easy 2x coming
Mentions
#LX has gone down too much with low P/E, even though it’s Chinese credit company, it’s something that have to try!!
It’s crazy to me. We’re talking companies like LX down 7% while having a PE less than 4 and a dividend yield of like 6%.
[Lexeo Therapeutics Advances FDA Discussions for LX2006 - TipRanks.com](https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-advances-fda-discussions-for-lx2006?utm_source=webullapp.com&utm_medium=referral#google_vignette)
Internal employees are hyped up as well. Thats what you want to see as an Investor [Linkedin Post](https://i.postimg.cc/LX21wtTM/IMG-0759.png)
Poor ppl are weird. A new renter in my complex just signed a 2800 per month lease and leased a new tesla model 3 the redesign. Meanwhile my basic ass owns my unit here outright and I'm driving in a Honda LX I haven't washed in 2 months.
You're right. But if LX gains approval... its a game changer. Unlike LLY version (or any other in the market at the moment) - the LX version prevents rebound weight gain after cessation. NOVO can utilize their current weight loss formula and in conjuction pair with LX. 1st drop the weight and 2nd maintain the loss.
LX is quite behind. Probably just started human trials. Not sure if they completed IND but at this point it will be LLY first. And then LX will need to prove first in class as oral
Interesting battle between LLY and NOVO. If NOVO pet project LX9851 passes the finish line. NOVO will be ahead.
LX trending up nicely before earnings tomorrow pre market
Everyone gotta get in on LX!
LX earnings all. Calls to the walls. Said it here first 👀👀👀🚀
I gots AMD LX and OPEN. Legoooo
That's a base model 2WD LX with literally nothing, though.
Just looked up the market near me cause this advice has been old hat for years now. 2021 Civic LX with 62,000 miles listed for $20,895. 2026 Civic LX orders are open for $25,562. No miles, better warranty, better financing options. Yeah, you tell me which ones a better deal.
What does its drug do? This is an important distinction . If the bottom list hit (and ADIL will imo). They will sky rocket due to the conditions they will alleviate/big population with the issue. LXRX - drug LX9851 - prevent rebound weight gain IHXL - Sleep apnea oral drug. Only one other in test phase exists. ADIL - AD04 - Alcoholism recovery - precision drug. Unlike other AUD - the only drug where full cessation not required during treatment. Which is the toughest part in quitting/recovery process.
Lexicon Pharmaceuticals Inc. $**LXRX** -INPEFA (sotagliflozin) is the only approved dual SGLT1/2 inhibitor for heart failure, positioning Lexicon Pharmaceuticals (LXRX) with a differentiated asset in a market fueled by the world’s rapidly aging population. - Another drug - LX9851 is a first-in-class, oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5), discovered and developed by Lexicon Pharmaceuticals(Novo rights) represents a non-incretin mechanism with animal data suggesting it might do what others cannot: when combined with semaglutide (Wegovy), it produced deeper weight loss and uniquely prevented weight regain after stopping GLP-1s—one of the central clinical challenges in obesity management. - Novo could offer a unique treatment paradigm—initial weight loss with semaglutide, sustained by adding LX9851 or using LX9851 after GLP-1 cessation—giving it a powerful, exclusive multi-step regimen few rivals could match.
Lexicon Pharmaceuticals inc ($**LXRX**) >INPEFA’s(FDA approved) only-in-class dual mechanism, proven cost-effectiveness, and targeting of an elderly, high-risk population make its profit pipeline compelling and robust—as heart failure and associated comorbidities rise with the aging demographic and as the CHF market grows globally. >Lexicon’s financial reports show early but growing INPEFA sales in the US heart failure market as payer coverage expands, with further potential upside as more robust evidence and new indications (such as hypertrophic cardiomyopathy and chronic kidney disease) are developed. >Global commercialization - Viatris paid $25 million upfront to Lexicon Pharmaceuticals (LXRX) in October 2024 as part of a global licensing agreement for exclusive rights to commercialize sotagliflozin (INPEFA) in all markets outside the US and Europe. >Another drug - LX9851(Novo Nordisk partnership 75m upfront payment with 1B in milestones payments) represents a first-in-class oral, non-incretin mechanism with animal data suggesting it might do what others cannot: when combined with semaglutide (Wegovy), it produced deeper weight loss and uniquely prevented weight regain after stopping GLP-1s—one of the central clinical challenges in obesity management. >Novo could offer a unique treatment paradigm—initial weight loss with semaglutide, sustained by adding LX9851 or using LX9851 after GLP-1 cessation—giving it a powerful, exclusive multi-step regimen few rivals could match.
LXRX having a great day. Lets go! >Lexicon’s Genome5000™ program. This is a proprietary genomics-based target discovery platform in which Lexicon scientists systematically studied the function of nearly 5,000 genes to identify more than 100 protein targets with therapeutic potential across various diseases. The Genome5000™ platform uses advanced gene knockout technology to validate targets and accelerate the discovery of innovative medicines. LX9851 and its ACSL5 target were discovered through this genomics-driven approach, demonstrating the platform’s ability to generate novel, high-value drug candidates for major unmet needs. LXRX and Novo Nordisk’s partnership centers on LX9851, a novel obesity drug discovered using Lexicon’s Genome5000™ genomics platform.
Nice. I plan on taking my LX up to 500k while adventuring around with it.
Yep, currently driving an LX570 with 160k on it. Not a single issue.
I listen to this - [https://www.youtube.com/watch?v=LX-7AnOx22k](https://www.youtube.com/watch?v=LX-7AnOx22k)
[https://www.youtube.com/watch?v=LX-7AnOx22k](https://www.youtube.com/watch?v=LX-7AnOx22k)
🚨Strategic opinion on $LXRX and Novo Nordisk (not financial advice) Lexicon has a deal of up to $1 billion with Novo Nordisk for its therapies (such as LX9851 and Zynquista). 75M have already been paid, but if the milestones are met, Novo will end up paying much more. 💭 From a financial point of view, it might make more sense for Novo to buy Lexicon outright than to continue paying for milestones. ➡️ Why? Full control of the pipeline. Acceleration of development. Long-term savings. They avoid paying up to 1B if they buy now for less. This is not a confirmed rumor, just a strategic reflection based on the agreements already signed. 👉 A takeover bid would not be unreasonable... and perhaps even cheaper than fulfilling the entire agreement.
Your way off on price, the largest shareholder who is also chair of the board will only take min $5+ or $2.5b. This is why it’s not ready for sale yet, they need the Phase3 on LX9211 or progress on other areas first. I am highly convinced of a partnership and a $2 share price this year.
A possible takeover bid for Lexicon Pharmaceuticals (LXRX) could be reasonable and legal if certain structural, strategic and financial factors exist that justify a buyer (such as Novo Nordisk or another pharmaceutical company) seeing sense in acquiring it. Below I detail the logical, legal and financial reasons that could support this hypothesis: 🧠 LEGAL AND STRATEGIC REASONING OF A POSSIBLE TAKEOVER OF LEXICON 1. ✅ Legality: is a takeover bid viable? Yes, legally any public company can be the subject of a takeover bid if: The buyer offers an attractive premium over the market price. Report to the SEC (in the US) using the Schedule TO form. Meets transparency and fairness requirements (SEC Rule 14d). The approval of the Board of Directors is obtained (if it is a friendly takeover bid) or pressure is applied with a hostile takeover bid if there is resistance. 👉 LXRX does not have public antitakeover clauses or structures with dual voting shares (like Alphabet or Meta), so it is legally vulnerable to a takeover. 2. 🎯 Strategic reasons for a takeover bid A. Undervalued valuable assets LXRX has approved drugs (such as Inpefa) and others in clinical phases, with high potential value in the medium term. The agreement with Novo Nordisk already demonstrates third-party interest in its assets (e.g. LX9851). Its current capitalization (~$250 M) is much lower than the value that its products could generate if they entered the global market. B. Savings in marketing costs A buyer with a global commercial structure (such as Novo or AstraZeneca) could scale Inpefa without duplicating costs, accelerating profits and profitability. C. Synergies Integrating LXRX would allow us to take advantage of clinical data, patents, scientific personnel and development pipelines without starting from scratch. 3. 💰 Financial reasons for a takeover bid A. Affordable purchase price With a market cap of ~$250 M, a takeover bid of $500–600 M ($2–2.50 per share) would be feasible and attractive.
That and the capriciousness of the orange goon. Just announced… https://on.ft.com/43hH6LX Trump orders US chip designers to stop selling to China
Exton and Granowitz, MD have made it clear they are looking to partner. Artal knows LXRX cannot launch in HCM or pain as evidenced by the sota launch failure. Is it a partnership or acquisition and I thought Pfizer best suited over AZ or Lilly. However, Vertex needs LX9211 for chronic pain. VX-548 is not the answer … no fast track from the fda like lx9211.
They should bring back the early 90s 5L LX with straight pipes
For LX9815 three years to market…
Damn, this $LXRX setup is juicy with all those catalysts coming! Their pipeline is looking solid with LX9211 Phase 2b DPNP data coming Q1 2025 and the ongoing Phase 3 SONATA HCM study. That $25M upfront with potential for $197M in additional milestones is massive for a company trading at these levels. And they've already got an FDA-approved product with INPEFA actually generating revenue - rare for sub-$1 biotechs. Thanks for sharing the chart - will definitely be watching this one closely alongside my core positions. Could be a great end-of-year runner! May use it as a play while I wait for the next leg of $AITX
[Subreddit theme song](https://www.youtube.com/watch?v=LX-7AnOx22k)
I watch the [Dow Janes YouTube channel ](https://www.youtube.com/channel/UCjYpaa0qSxg0IqAGW1LX1yA)and find it really helpful and interesting. I know that some think that there isn't a difference between men and women for investing, but there really is - it's just the way it is. Anyway, Dow Janes is super. And it's not 'pink', as you put it. LOL
Here's my take as someone in the biomed industry: Missed some key metrics on LX9211 (a drug with already limited use since Gabapentin shows long-term effectiveness for neuropathic pain) and didn't secure a partnership for it. This tanked the stock as it is uncommon for no partnership with drugs that meet most objectives. They partnered with NN for LX9851 and it jumped higher than it should've because people locked in on the 1bn deal, likely not understanding the grueling research and regulatory milestones the drug still has to meet before it'll see 90% of that funding. I think people are realizing this nown while also drawing concerning potential parallels with the aforementioned LX9211. Pair that with the fact that 2-fluoropalmitic acid already achieves inhibition of sphingosine/acly-CoA, and we can surmise that although LX9851 will be profitable if/when it is finally approved, it isn't as revolutionary as LXRX tries to tell us. 2-fluoropalmitic acid
LXRX - Very underrated stock and it just crossed past its resistance price of .50, volume and price also been picking up today. Analysts price target of $4 Strong catalysts due to development of LX9851, in a deal potentially worth up to $1 billion from Novo Nordisk partnership and license agreement. This includes upfront and near-term milestone payments of up to $75 million.
You spend your time daydreaming about your future working at Wendys. I spend my time studying and learning about the Stäubli LX160 Jacquard Machine so I can be one of the top Textile employees when we all get forced to work in shitty factories We are not the same
I have been in since before phase 2b results for LX9211 and was planning on holding until a partnership if data showed similar efficacy or better, and similar tolerability or better. Data showed similar efficacy, and increased tolerability following loading dose removal so I held. SP didn't react as I would have liked but still trading my plan. Decreased cash burn, and partnership with Novo on LX9851 have been nice additions, but I am still here for the LX9211 partnership which I suspect will come in the next couple months. Just following my DD at this point, so it is easy to hold cause I am willing to take the risk since I did my research and win or lose it's on me. there is a peace that comes with that. Not sure about a target price, or the chance. I will probably start selling pieces off over $1, but a lot hinges on the magnitude of the news and how the market reacts
https://preview.redd.it/go37vxrdxyre1.png?width=983&format=png&auto=webp&s=b463cab0d7e03ca9e768f916cbc63a359201aa11 This is basically a summary: the fact that $NVO trusts $LXRX is a big deal "Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Lexicon is eligible to receive upfront up to $75 million. In total, Lexicon will be eligible to receive $1 billion"
Its in the press release: "Preclinical in vivo efficacy data from the first study showed that treatment with LX9851 resulted in significant reductions in weight, food intake and fat mass in diet-induced obese (DIO) mice. " https://investors.lexpharma.com/news-releases/news-release-details/lexicon-present-preclinical-vivo-efficacy-data-demonstrating Of course I hope it goes well but just saying, the drug isn't fully developed and approved yet. Still doesn't change that Novo seems to very confident (or they may just have a little to much cash around)
I know. I literally bought in on the exact day it tanked 60%. Main reason is market overreaction to this news: Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ:LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the efficacy of Pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain (DPNP). Despite achieving meaningful pain reduction and tolerability in the 10 mg dose, the study failed to reach statistical significance on the primary endpoint, leading to a sharp decline in investor confidence.
I was there for almost 20 days. Rented a car and drove all over. Was up north in Porto, South in Algarve. Lisbon was a lot of fun. Had the most fun down south in the Algarve, but I like to hike and go to random beaches so not really much "sightseeing". It was like €15 a day for the rental car with Sixt, my credit card covered the insurance. They even upgraded me to a really nice SUV. In Lisbon, check out LX Factory in the evenings. Was worth an hour or two to check out some shops and get food. Look for Tabernas and Tascas (like local eateries. Food is cheap and really good). Go to Amago for dinner if you can get a reservation. Turkey, as long as you don't eat at the tourist trap spots things were pretty reasonable. Had a nice hotel room in Taksim area for like $90 a night
Honestly I’m pretty sure inflation is down bc that $100k car is now selling for $90k. Eggs and stuff have gone up in price. I’m not buying the new Lexus LX. I’m buying the eggs.
That’s what I was thinking, we did the same, spent over $100k (Lexus LX), but 0% interest for 5 years, so that cash has stayed in a HYSA the whole time. Always have it sitting there just in case. I’ll admit, it’s been hard sometimes not paying it off since we are not used to car payments, but then remind myself that it’s free money.
Your numbers on the success of Phase 2 trials are not applicable here because this is the second Phase 2 study. The first was successful but not a complete Phase 2 because it lacked diverse demographics. The initial Phase 2 study was successful and showed a statistically significant pain reduction with LX9211 at 10mg. Google: LX9211 Reduces Diabetic Nerve Pain, Improves Quality of Life in Phase 2 Trial. https://www.hcplive.com/view/lx9211-reduces-diabetic-nerve-pain-improves-quality-of-life-in-phase-2-trial The article states: Use of LX9211 was associated with clinically significant benefits for people with diabetic peripheral neuropathic pain, according to results of the phase 2 RELIEF-DPN 1 trial.
💯 my dude. The Lancet data is straight fire - first SGLT drug to crush both heart attacks AND strokes. Institutions know what's up, loading the boat before LX9211 data drops. Bears gonna get rekt when those 43M short shares need covering 🚀
put it here! www.marcus.com/share/DAN-8LX-IXK6
here is my link. support freedom https://www.marcus.com/share/DAN-8LX-IXK6
I agree. Also, LX9211 has been “fast tracked” for approval by the FDA. There is also the slim possibility that it could get a nod for “Accelerated Approval” which would allow it to enter the market in an even shorter timeline while ongoing trials were completed and data was shared with the FDA.
This is a great breakdown, thanks for taking the time to contribute this. Completely speculative here but I'm also hopeful because they recently (just a few days ago) updated their pipeline by providing a drug name for LX9211 (pilvapadin). Given how everyone is aware phase 2b results are the critical point for the company, I'm not sure why they would provide it with a name unless they were confident it can move ahead to phase 3 (which is dependent on positive 2b results). Again, it's speculative but this makes me more confident.
The research study analysis from the first study of LX9211 states it should be classified as a Stage2a trial. (It was not because the demographical data did not have enough variation.) Statistically significant pain reduction was noted at 10mg, but failed at higher doses. However, it was noted that the higher doses may have declined due to failure to take the drug with increased adverse reactions including nausea and dizziness as time progressed. The Stage2b trial has a similar design to the original trial that showed statistically significant pain reduction at 10mg. (The new trial added a group of subjects receiving 20mg at 2 weeks followed by 10mg for 6 weeks to reduce the duration of adverse effects by lower the dose since the higher dose continued to show reduced pain after discontinuation of administration.) Essentially, the higher dose was more successful in relieving pain (resulting in a lower pain score) but could not be tolerated and constistantly taken for an extended period of time. I predict that the 10mg will show statistically significant pain reduction, but the model using 20mg for 2 weeks followed by 10mg for 6 weeks will show significantly more pain reduction and be statistically significant to warrant continuation with a Phase 3 model. If so, this could be a blockbuster drug as it would serve as an alternative to opioid pain relievers for neuropathy.
They know it’s a one trick pony, only LX9211 will move it up, a fail could see 100m market cap. They need something back in P1 but not obesity related as it’s too crowded for market interest. The molecules used for pain are a partnership so not sure what happens to licensing for them if fail.
It’s a difficult one to navigate, my position is at about 0.9 so may average down a bit soon. The issue I have is the LX9211 may not be read correctly by the market, it was in addition to standard care medication’s people where on, it’s not expected to be a stand alone I don’t think but enough demand exists for anything that improves the situation. I don’t think read out will be amazing but hopefully touch markers. The issue is the market players read on it, despite being ‘Ok’. I feel the bar is quite low in the area for commercial success. Any commercial success in pain is a big $. If stock goes down after read it will be hard to push up without takeover or partner news.
Thanks for this, You are correct that data being positive is speculative. However as explored within the DD there is reasoning for our optimism, rather than just a solely naïve hope. In particular, we reference the increase in institutional holdings in the last several months, even after negative FDA feedback of Sotafliglozin for one of its two use cases. Given how the SP has been run down since this event, and that the success of the LX9211 topline data will likely determine the future of the company, I still believe this will be a catalyst-level event (in either direction, but I believe upwards...) Like you say the Sotafliglozin drug has multiple use cases, meaning that the (cardiac) use case certainly doesn't have a great trajectory. Nevertheless it is still actually licensed by Viatris (multibillion dollar biopharmaceutical company) for the other use case. So it's not completely useless. This could also be a source of revenue in the upcoming earnings, although this is largely speculative. There's been a few articles published recently as well in the news (as linked in DD) highlighting it's efficacy for its use case. Either way the company did abandon its commercial activities for Sotafliglozin, leaving it to Viatris. They released a PR a few months back saying they were cost-cutting to focus on their pipeline. With regards to the cash position, public biopharmaceutical companies avoid bankruptcy through dilution which raises capital. Assuming they can find no partnerships, they will do dilution to raise money like you say. Bankruptcy isn't really on the cards in my opinion. Anyway, this is a short-term position playing a near-term catalyst. As you say they have a cash runway of a year, meaning that the dilution risk (not the bankruptcy risk) is low in the short term as they have lots of cash to run operations, importantly phase 3 trials. As to earnings, I don't know what may come out of it. I'm not sure it's cash position being the sole determinant of the market cap is completely accurate though. It may be a factor, but I don't think the SP would "tank" based on a smaller cash position given that with these small biopharma companies the primary SP determiners are their pipeline (and not cash position, except in some cases where there is clearly barely any left raising immediate risk of dilution). Still, I completely recognise the risk involved in this speculation which is why I label this as a medium/high-risk play as per the post.
Thanks for this. You are correct that data being positive is speculative. However as explored within the DD there is reasoning for our optimism, rather than just a solely naïve hope. In particular, we reference the increase in institutional holdings in the last several months, even after negative FDA feedback of Sotafliglozin for one of its two use cases. Given how the SP has been run down since this event, and that the success of the LX9211 topline data will likely determine the future of the company, I still believe this will be a catalyst-level event (in either direction, but I believe upwards...) Like you say the Sotafliglozin drug has multiple use cases, meaning that the (cardiac) use case certainly doesn't have a great trajectory. Nevertheless it is still actually licensed by Viatris (multibillion dollar biopharmaceutical company) for the other use case. So it's not completely useless. This could also be a source of revenue in the upcoming earnings, although this is largely speculative. There's been a few articles published recently as well in the news (as linked in DD) highlighting it's efficacy for its use case. Either way the company did abandon its commercial activities for Sotafliglozin, leaving it to Viatris. They released a PR a few months back saying they were cost-cutting to focus on their pipeline. With regards to the cash position, public biopharmaceutical companies avoid bankruptcy through dilution which raises capital. Assuming they can find no partnerships, they will do dilution to raise money like you say. Bankruptcy isn't really on the cards in my opinion. Anyway, this is a short-term position playing a near-term catalyst. As you say they have a cash runway of a year, meaning that the dilution risk (not the bankruptcy risk) is low in the short term as they have lots of cash to run operations, importantly phase 3 trials. As to earnings, I don't know what may come out of it. I'm not sure it's cash position being the sole determinant of the market cap is completely accurate though. It may be a factor, but I don't think the SP would "tank" based on a smaller cash position given that with these small biopharma companies the primary SP determiners are their pipeline (and not cash position, except in some cases where there is clearly barely any left raising immediate risk of dilution). Still, I completely recognise the risk involved in this speculation which is why I label this as a medium/high-risk play as per the post.
Got one for y’all. LXRX Upcoming catalyst. Lexicon Pharmaceuticals began enrollment for their phase 2b study of LX9211 on November 26th 2024. Given that topline data is typically published at least 12 weeks onwards, we can expect topline results to be published between the 18th February and mid-March 2025. The market has shown a history of reacting positively to previous data readouts, meaning that we can expect the same for phase 2b readout; although, possibly at a larger scale.
Our new anthem https://youtu.be/LX-7AnOx22k?si=nEoDorgw_ncwmSOP
Detroit News (01/26/2025): ['About time': Why car dealers see upside in Trump's return to office](https://archive.ph/g14LX#selection-363.0-363.68)
Your data is outdated, Zeta Global (NYSE: ZETA) announced that CEO David A. Steinberg, company leadership, and board members plan to purchase approximately $3 million worth of Class A common stock on **November 18, 2024**. https://www.stocktitan.net/news/ZETA/zeta-global-announces-intended-share-purchases-by-ceo-and-members-of-hptntkh3adzt.html#:\~:text=Zeta%20Global%20(NYSE%3A%20ZETA),false%20claims%20about%20the%20company. **Zeta Announces $100 Million Stock Repurchase Program** [https://finance.yahoo.com/news/zeta-announces-100-million-stock-024900912.html?guccounter=1&guce\_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce\_referrer\_sig=AQAAAIHB9F9Td7PpazX6oI2w80wTHY9iTx-LgSKYFdj0-ruwtKzzfbtdfMMEBP-QxDTS9BxwW5i9sxeLdbEN\_iOmsBn8-FbCXGuQUy2LX4Ip-H7mMuOqHlNh\_pg0gLA2k0ksk8n-kQOBBvXAvko79UTDP4mJCadl1koaiXFG8F5aBgxA](https://finance.yahoo.com/news/zeta-announces-100-million-stock-024900912.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIHB9F9Td7PpazX6oI2w80wTHY9iTx-LgSKYFdj0-ruwtKzzfbtdfMMEBP-QxDTS9BxwW5i9sxeLdbEN_iOmsBn8-FbCXGuQUy2LX4Ip-H7mMuOqHlNh_pg0gLA2k0ksk8n-kQOBBvXAvko79UTDP4mJCadl1koaiXFG8F5aBgxA)
Same. Everyone shits on jeep, and it’s people who had liberties or renegades and the like, acting like they’re 100k cars. GC in 2011 was a game changer as was the LX platform, and then the JLs and Wagoneers. Arguably one of the best SUV lineups available. Polished, high quality interior finishes and tech, and good power/economy while offering value against upmarket competitors. People compare jeep to ford and Chevy, and that’s just not accurate - it is a luxury brand that competes with Europeans and Lincoln/Caddy, with a better product. A grand Wagoneer is vastly superior to the Escalade and Navigator.
HUT, SMLR, LX, FINV !remindme 1y
I wonder why it wouldn't let me make a banbet for LX.
Thank you for sharing!! Taking a look while I enter LX before it leaves the penny stock realm
LX and HUT going crazy Also another stock slightly too small to mention. Will probably be big enough in a week's time.
I went from a ford ranger to a Honda civic LX to a Honda accord top of the line to a Subaru Outback 3.6r. I only drive about 12k a year and also ride a motorcycle all summer long. So the gas in my Outback hasn’t been an issue. And it’s been bullet proof for a decade. My next car which will likely be my last new car purchase will be some too of the line luxury car because I can afford it and I want it for my wife and I when we drive places. I also will drive it into the ground! As I said before. I think OP is applying their personal view and issues. I think most people fall into the two camps of overpaying for cars. Or paying what they are happy to spend on a car.
I will either be very happy, or very not. 
Glad I didn't invest that much into $YINN, I'll only have to spend 2 days behind Wendy's instead of 3 TIGR, LX, and DADA look fine though. Not a huge pump but they're up slightly (so far, anyway)
I literally sold my calls on LX today got only a $200 profit but I’m just glad I didn’t try to wait it out
For me, YINN is the riskiest and DADA + LX are (comparatively) safer bets.
Here are a few things you should keep in mind: 1. This is a degenerate gamble 2. It's a pure speculation that has worked really well so far That being said, I'm already in the following positions: LX 5c 10/18 DADA 2.5c 10/18 YINN 74c 10/18 DADA is up 99% in the last 30 days and still a market Cap of $590 M with a PE of -1.99 (negative PE) LX is up 108% in the last 30 days and still a market Cap of $620 M with a PE of 5.2 All these stocks have been absolutely destroyed (unfairly to a large extent, but some of it was warranted). Now combine the above information with the fact that Xi/CCP are going to inject $1 TRILLION into the Chinese Stock Market over several months. Shanghai Stock Exchange is Closed For a national holiday from 10/01 to 10/07. It opens on Tuesday, and I suspect that the Chinese people are gonna go berserk and buy like there's no tomorrow! Also, look at the US hedge Funds piling into China. Of course they can drop faster than a hot potato, but I'm gambling on them skyrocketing at least in the short term.
POSITIONS: DADA 2.5c 10/18 LX 5c 10/18 YINN 74c 10/18 And a few other 10/18 calls
DADA 10/18 2.5C LX 10/18 5c
I'm mostly playing small caps because they tend to be more volatile and move ups are usually insane! LX-DADA-NIO-YINN Though everything China should move together!
POSITIONS: Calls 10/18 DADA LX NIO YINN
I don't know if it's late or not. However I feel like The Chinese Government will keep pumping the market for at least a few weeks. This is not an investment advice. This is a pure gamble that's paying off really well  I have the following calls: all 10/18 NIO LX DADA
https://preview.redd.it/rwhttrbuccsd1.jpeg?width=1440&format=pjpg&auto=webp&s=85ecfa14f1aeab8738d3f0c7054a9d5d2379a738 . $LX
This is pre-market. LX is up another 22% premarket. 
Time to get in is now. We’re only at the starting blocks! I’m in $LX, sure this will run heavy again today. The volume yesterday was huge!
Amazon is a tech by not paying dividend. AWS. S&P500 85% momentum is magnificant 7, rest is the 501-7 stocks. A good year it returns good but an overhyped AI clouds their future since earnings do not support their massive spendings. Look for something that prospers when interest declines. SPDR funds has etf in each sector. LX & E,,F, K,V,U, I, P etc. E is energy which we have plenty of so you skip that sector. K is tech whihc you already got a lot. I own XLY, XLP but that is just me.
That have to recall 100k engines on Tundra and LX Lexus with 3.6 twin turbo engines, they still have no clue how to fix it so they a just replacing them with no cost to customers and it gonna cost huge
Can I bet somewhere that Kendrick will do a halftime show at either the Super Bowl LX or LXI which will both be played in california?
a 50% gain over 10 years? [This link](https://www.wealthmeta.com/calculator/portfolio-allocation-calculator) shows the cagr of the 60/40 from 2014-2023 (the latest date the have data for) as 7.9% [We can use a compound interest calculator ](https://www.nerdwallet.com/calculator/compound-interest-calculator?utm_source=goog&utm_medium=cpc&utm_campaign=bk_mktg_paid_092723_banking_dsa_mobile&utm_term=&utm_content=ta&mktg_hline=19335&mktg_body=2989&mktg_place=dsa-2206538784443&gad_source=1&gclid=CjwKCAjwyo60BhBiEiwAHmVLJQEzmyE1b-m2LX2syqIPpDZQ_eSN36e_LxgfZ9SJriYpatyiZ-X-1RoCeDgQAvD_BwE&gclsrc=aw.ds) to show if his 401k was, say 5k, in 2014 and he made no other contributions it should have a final balance of $10695. Or over 100% from the initial investment. So his "financial advisor" underperformed the 60/40, the absolute benchmark all portfolio's will always get measured against, but a drastic amount. So, now that we've established how poorly the "professional" has preformed we have to ask ourselves one question. Are all these trades due to portfolio rebalances to increase risk adjusted returns? Or is he churning the portfolio to generate more fees for himself? I think we both know the answer. And in case you can't see it I'll be direct and tell you. Its the latter option I presented not whatever dumb shit you were saying.
[I used this song to get hyped before this trade](https://music.youtube.com/watch?v=SD5kS1hzL-U&si=d1_zKeQk8uV4LX2X)
Yeah, like the deal they just made with OpenAI and Google. The Google deal alone is $60M/year. Ongoing revenue is great. A quote from [this article](https://techcrunch.com/2024/05/16/openai-inks-deal-to-train-ai-on-reddit-data/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAL4gTQH061KfDgxdKboUcA2BUPtra0LX0es_DjsiD-XCnKF38zRUG6-aDoeMPfN_N3kLvx7M2OAc2b_aYRmTt3KTftBpoJD4ZwXWZ0TjWkwfjwSf1k10LIFCfKAhuPjB-GpqiKvivQ4E8RvRy4wgTs30eaG0liKIRsAMmM03vedg): "The paradox I see is that, as more content on the internet is written by machines, there’s an increasing premium on content that comes from real people,” Reddit CEO Steve Huffman said during the company’s earnings call in March. “And we have nearly two decades of authentic conversation.”
would you rather get a Lexus LX 570 or Land Cruiser?
Daily drivers... Me: 2013 Lexus RX(13k miles), paid 25k, hubs: 08 Camry(120k miles) for 3k. We also have a 21 LX(45k miles), paid 68k w/bumper to bumper warranty until 2031 & tires for 5y(1st owner smoked in it, so we got it for 15% less than others at the time). That's the whole family/stormy weather car(we have 5 kids, but we rarely all need/want to be in the same place), so this one should hold value. Depreciation too high for a daily driver.
[I’m having unstuffed cabbage for dinner](https://imgur.com/gallery/ae7x3LX) Still no workout 😔
Thanks for your advice. The stock market this year will be a great opportunity if you invest too. Join this US stock market group and take advantage of this year’s rising market! The latest market analysis and trading information are provided here for your reference, with an average weekly increase of more than 30%. Everything is free (all investors are welcome to join) [https://chat.whatsapp.com/GNQ7yN8RB5x7Qe1JzBivOv](https://chat.whatsapp.com/GNQ7yN8RB5x7Qe1JzBivOv?fbclid=IwZXh0bgNhZW0CMTAAAR0FhP_RggiwzKbJ2n6DTEp9S5leIi-i8YnugRU5yTpIHDmX62zSBgvfx1c_aem_AXpyCvNObFAAxKYh_iCz0vMkyIOGTbVItXHm7-4D6gKrRXTAN5zXAuHFKtD4Tw9D90BtknGHyFtwt22E_47hWW1l)[](https://chat.whatsapp.com/GNQ7yN8RB5x7Qe1JzBivOv?fbclid=IwZXh0bgNhZW0CMTAAAR2XNAn0u_8z0t2Z8CDafGeLHwv4lS1dI6dZWT7LX2vYY3X3KpgA-pbKa4A_aem_AXobvejGHxY6qfrtpaEoWlq1DhlFcnWpbRh3LcK9qs_78gxRjwCPth2y75s97zK8s-4DxjmFYZhM0_fOQJMrPC2F)
Bought 3 hours ago LX32TW for ~4k. Hopefully, it will be quick money.
Good news! In the automotive world, a "luxury car" is actually advertised as such, so you don't have to even think about it, and price =/= luxury. Here's a primer: |Mass brand|Luxury brand| |:-|:-| |Toyota|Lexus (1989)| |Honda|Acura (1986)| |Nissan|Infiniti (1989)| |Hyundai|Genesis (2015 officially)| |GM: Chevy, Buick is "mid-tier"|Cadilliac| |Ford|Lincoln (1922)| |VW|Audi, Bentley| |DaimlerChrysler: Chrysler|Mercedes-Benz| |BMW Group: Mini|BMW, Rolls-Royce| An e.g. of price =/= luxury: 2021 Toyota Land Cruiser $85.5K vs it's luxury cousin 2021 Lexus LX 570 $86.9K. The Toyota Land Cruiser is NOT a luxury car, it's simply known as a...legend.
Good news! In the automotive world, a "luxury car" is actually advertised as such, so you don't have to even think about it, and price =/= luxury. Here's a primer: |Mass brand|Luxury brand| |:-|:-| |Toyota|Lexus (1989)| |Honda|Acura (1986)| |Nissan|Infiniti (1989)| |Hyundai|Genesis (2015 officially)| |GM: Chevy, Buick is "mid-tier"|Cadilliac| |Ford|Lincoln (1922)| |VW|Audi, Bentley| |DaimlerChrysler: Chrysler|Mercedes-Benz| |BMW Group: Mini|BMW, Rolls-Royce| An e.g. of price =/= luxury: 2021 Toyota Land Cruiser $85.5K vs it's luxury cousin 2021 Lexus LX 570 $86.9K. The Toyota Land Cruiser is NOT a luxury car, it's simply known as a...legend.
I was at a Safeway parking lot right about to get in my Lexus LX and I see this woman with her man checking out me probably cause of the car. I was lowkey mad for the guy and it reminded me that these hoes ain’t loyal
Go check out Chinese ADRs! I have been digging around and found stocks that are so crazily cheap: Stock 1): LX : PE ratio 2x, Dividend yield: 10%+ , it is an internet fintech providing consumer finance to Chinese consumers (like AFRM!). Its dividend payout ratio is 20-40%. Its peer, QFIN, just announced a steller 4Q23 earnings (stock + 10% just now): BZUN : PS ratio : 0.14x !!!! it is an internet value add service provider helping companies manage ecommerce in China. It went downstream (purchased the clothing brand GAP's distributing rights in China). For me, it's time to sell some NVDA and go yolo on these ADRs !!